![]() |
|
|
Vol. 298, Issue 1, 234-239, July 2001
Institut National de la Sante et de la Recherche Medicale U456,
Détoxication et Réparation Tissulaire, Faculté des
Sciences Pharmaceutiques et Biologiques, Université de Rennes I,
Rennes, France
Metals, such as arsenic or cadmium, have recently been
demonstrated to interact with metabolic pathways, including phase I and
phase II enzymes and the phase III efflux pump P-glycoprotein. In the
present study, we investigated the effects of heavy metals and
metalloids on the expression of the multidrug resistance-associated protein 2 (MRP2), a major hepatic transporter. Treatment of primary rat
hepatocytes by sodium arsenite [As(III)], sodium arsenate and
potassium antimony tartrate, but not cadmium chloride, was shown to
markedly increase MRP2 mRNA and protein levels; As(III)-mediated induction was dose- and time-dependent and paralleled a strong increase
in MRP2 amounts as assessed by Western blotting. As(III) was also
demonstrated to markedly up-regulate MRP2 gene expression in primary
human hepatocytes. MRP2 mRNA induction occurring in As(III)-treated rat
hepatocytes was fully blocked by actinomycin D, indicating that it
required active gene transcription. It was associated with an
activation of the c-Jun N-terminal kinase pathway and
with a reduction of cellular glutathione levels. Quercetin, a flavonoid
compound known to block As(III)-related induction of P-glycoprotein,
was also found to prevent up-regulation of MRP2 gene expression in rat
hepatocytes exposed to As(III). Such an effect was unlikely to be due
to alteration of JNK pathway since quercetin failed to abolish
As(III)-induced JNK phosphorylation. It may rather be linked to the
increase of cellular glutathione levels by quercetin, thus limiting the
depleting effects of As(III) on glutathione amounts. Finally, these
results confirm that some metals strongly regulate expression of
detoxifying proteins, including biliary drug transporters.
This article has been cited by other articles:
![]() |
G. Williamson, I. Aeberli, L. Miguet, Z. Zhang, M.-B. Sanchez, V. Crespy, D. Barron, P. Needs, P. A. Kroon, H. Glavinas, et al. Interaction of Positional Isomers of Quercetin Glucuronides with the Transporter ABCC2 (cMOAT, MRP2) Drug Metab. Dispos., August 1, 2007; 35(8): 1262 - 1268. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. S. Miller, J. R. Shaw, C. R. Stanton, R. Barnaby, K. H. Karlson, J. W. Hamilton, and B. A. Stanton MRP2 and Acquired Tolerance to Inorganic Arsenic in the Kidney of Killifish (Fundulus heteroclitus) Toxicol. Sci., May 1, 2007; 97(1): 103 - 110. [Abstract] [Full Text] [PDF] |
||||
![]() |
T.-C. Lee, I-C. Ho, W.-J. Lu, and J.-d. Huang Enhanced Expression of Multidrug resistance-associated Protein 2 and Reduced Expression of Aquaglyceroporin 3 in an Arsenic-resistant Human Cell Line J. Biol. Chem., July 7, 2006; 281(27): 18401 - 18407. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Cui, Y. Kobayashi, T. Hayakawa, and S. Hirano Arsenic Speciation in Bile and Urine Following Oral and Intravenous Exposure to Inorganic and Organic Arsenics in Rats Toxicol. Sci., December 1, 2004; 82(2): 478 - 487. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Liu and B. Chen Copper treatment alters the barrier functions of human intestinal Caco-2 cells: involving tight junctions and P-glycoprotein Human and Experimental Toxicology, August 1, 2004; 23(8): 369 - 377. [Abstract] [PDF] |
||||
![]() |
L. Vernhet, N. Allain, M. Le Vee, F. Morel, A. Guillouzo, and O. Fardel Blockage of Multidrug Resistance-Associated Proteins Potentiates the Inhibitory Effects of Arsenic Trioxide on CYP1A1 Induction by Polycyclic Aromatic Hydrocarbons J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 145 - 155. [Abstract] [Full Text] [PDF] |
||||